BioGenCell Completes Seed Funding of $16M


BioGenCell, a Netanya, Israel-based biotechnology company, raised $16M in Seed funding.

Marius Nacht led the round.

The funds will be used by the company to help it develop.

Founded by Dr. Yael Porat and Prof. Michael Belkin, BioGenCell is a biotechnology company that develops technology for using stem cells from the patient’s own blood to treat microvascular diseases.

BioGenCell’s medical platform focuses on the needs of patients and physicians. The current product treats severe, limb-threatening ischemia (CLI), which is a condition that’s most commonly found in diabetics and smokers. The patented treatment involves the manipulation of stem cells and other cells from patients in standard blood draws. These cells are then reinjected into leg muscles. The injection cell mixture stimulates the formation of new blood vessels, bypassing the damaged ones, and thus renews blood flow to the leg. This reduces inflammation and repairs the damage from the inflammation. Cell reinjection can be performed in any room that is equipped with standard treatment.

In its Phase I clinical trials, BioGenCell treated five patients who had previously tried all the other available treatments and were about to undergo leg amputation. Four more cases of serious compassion were treated by the company. The treatment was safe. Although each patient has a different condition, all patients experienced improvements in at least three parameters. These included prevention of amputations, increased blood flow, healing chronic sores, and the ability to walk. There were also subjective parameters such as lower pain, which allowed for weaning off narcotics and a better quality of life. These patients show that the treatment has a lasting therapeutic effect.

FDA approval was granted to the company to continue with Phase II controlled, double blinded trials. If successful, Its future product line, based on its technology, includes those to restore blood vessels related to kidney failure, pulmonary hypertension, heart failure, stroke, blindness, and more.

BioGenCell is located at and has a strategic partnership with Laniado Hospital in Netanya, Israel.

Get latest news from African Startup ecosystem

Latest stories

You might also like...